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Objectives: Cardiopulmonary bypass is associated with a systemic in-
flammatory response syndrome and the risk of multiorgan injuries me-
diated by activated polymorphonuclear leukocytes. Phosphodiesterase
type 4 is the predominant phosphodiesterase isozyme in polymorphonu-
clear leukocytes and plays a key role in the regulation of polymorpho-
nuclear leukocyte activation. The aim of this study was to examine the
effect of rolipram, a selective phosphodiesterase type 4 inhibitor, on the
functional changes of polymorphonuclear leukocytes by using simulated
extracorporeal circulation.
Methods: Simulated extracorporeal circulation was established by recir-
culating heparinized human blood for 120 minutes on a membrane
oxygenator with and without 10 mol/L rolipram. F-actin content and
L-selectin and CD11b expression of polymorphonuclear leukocytes were
measured by means of flow cytometry. Polymorphonuclear leukocyte
deformability was evaluated with a microchannel array flow analyzer that had a
similar diameter as the capillaries. Polymorphonuclear leukocyte elastase was
measured with an enzyme immunoassay.
Results: Rolipram reduced the increase of F-actin content of polymorphonuclear
leukocytes and the increase of transit time of 100 L of blood sample through a
microchannel. Rolipram reduced the increase of CD11b expression and the decrease
of L-selectin expression of polymorphonuclear leukocytes. Rolipram reduced the
release of elastase from polymorphonuclear leukocytes.
Conclusion: Rolipram inhibited the deformability change mediated by F-actin
assembly, the changes in adhesion molecules, and the release of elastase from
activated polymorphonuclear leukocytes in simulated extracorporeal circulation.
This study suggests that phosphodiesterase type 4 inhibition could be a feasible
therapeutic strategy to prevent the exaggerated inflammatory response related to
cardiopulmonary bypass.
Cardiopulmonary bypass (CPB) is associated with a systemic inflam-matory response syndrome, and patients who undergo CPB are atrisk of organ injuries typical of acute respiratory distress syndrome.It is well documented that injuries associated with CPB are medi-ated by activated polymorphonuclear leukocytes (PMNs),1,2 andPMN sequestration in microvessels is the initial important step.3,4
Activated PMNs sequester in microvessels because of the decrease of their deform-
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ability5 and the increase of adhesive qualities of PMNs and
endothelial cells.6 The decrease in deformability of PMNs is
mediated by a rapid assembly of filamentous F-actin from
soluble G-actin at the cell periphery.7,8 The selectins slow
PMNs by mediating rolling, and the integrins induce firm
adhesion between PMNs and endothelial cells.6 The inter-
action between these adhesion molecules on PMNs and
their ligands on endothelial cells contributes to prolonged
PMN sequestration in lung microvessels.9
Cyclic adenosine monophosphate (cAMP) is an intracel-
lular messenger that has a suppressant effect on leukocyte
activation.10 cAMP is inactivated by phosphodiesterase
(PDE), and PDE type 4 is the predominant PDE isozyme in
leukocytes.10 Specific PDE type 4 inhibitors increase cAMP
levels in PMNs and are reported to inhibit the increase of
cytosolic calcium in N-formyl-Met-Leu-Phe–stimulated hu-
man PMNs,11 which is a pivotal event in PMN activation.12
Our working hypothesis is that PDE type 4 inhibitor
inhibits the activation and inflammatory response of PMNs
during CPB. We used simulated extracorporeal circulation
(ECC), which has been used extensively in vitro, to model
inflammatory responses during in vivo CPB.13,14 The aim of
this study was to evaluate the effect of the PDE type 4
inhibitor rolipram on PMN activation by using simulated
ECC. We evaluated the effect of rolipram on PMN F-actin
assembly, the transit time of whole blood through micro-
channels, adhesion molecule expression, and the release of
elastase from PMNs.
Methods
Simulated ECC
The effect of ECC on the activation of PMNs was evaluated with
simulated ECC, as described previously in more detail.13,15 Each
perfusion circuit (surface area of 0.66 m2) was assembled from
silicone rubber tubing (one-quarter inch inside diameter; MERA
co, Tokyo, Japan), polycarbonate connectors, a polyvinyl chloride
venous reservoir bag (MERA), and a 0.6-m2 membrane oxygen-
ator (model 60EC, MERA). All components of the circuit were
sterilized and used once. Human blood (250 mL) was drawn from
healthy male donors (aged 25-40 years) through an 18-gauge
needle and polyvinyl tubing directly into a venous reservoir bag
containing heparin (3.75 U/mL). Donors abstained from all med-
ication for at least 2 weeks before donation. Written informed
consent was obtained from donors, and the protocol was approved
by the Institutional Review Board of the University of Tsukuba.
The perfusion circuit was filled with blood (control group, n 
6) or blood containing rolipram (10 mol/L final concentration;
BIOMOL Research Laboratories, Inc, Plymouth Meeting, Pa; ro-
lipram-treated group, n  6). Blood was recirculated by using a
barely occlusive roller pump (model MS-033, MERA) at 400
mL/min for 120 minutes. Oxygenators were ventilated with 95%
oxygen and 5% carbon dioxide at a rate of 0.7 L/min. Blood
temperature was maintained at 37°C by immersing the reservoir
bag in a shaking, constant-temperature water bath. Preliminary
experiments confirmed that the pH of the circulating blood was
kept from 7.3 to 7.5, and the activated clotting time was greater
than 500 seconds throughout the experimental period. Four blood
samples were drawn from the reservoir into polypropylene tubes
before recirculation (zero time) and 30, 60, and 120 minutes after
recirculation. The standing control sample (3.75 U/mL heparin)
was incubated for 120 minutes in a shaking water bath at 37°C
before processing. Blood samples for blood cell counts and dif-
ferential white cell counts were collected in tubes containing
potassium ethylene tetra-acetic acid (VT-052DK, Venoject;
Terumo Medical Corporation, Tokyo, Japan). Blood samples for
F-actin, CD11b, L-selectin, and the transit time of whole blood
through microchannels were collected into tubes containing acid-
citrate-dextrose (9:1 by volume). Blood samples for PMN elastase
were collected and centrifuged at 3000 rpm for 15 minutes, and the
supernatant was stored at 80°C until measurement.
Blood Cell Counts
Blood cell counts were performed with a counter (T-660; Beckman
Coulter, Inc, Fullerton, Calif), and differential white cell counts
were made on Wright-stained blood smears by an experienced
independent observer.
F-actin Content Assay
Fifty microliters of sample was fixed, and the cells were perme-
abilized with IntraPrep permeabilization reagent (Immunotech,
Coulter). PMNs were stained for 30 minutes in the dark at 37°C
with 1 U of BODIPY FL phallacidin (Molecular Probes Inc,
Eugene, Ore). Cells were washed twice with phosphate-buffered
saline solution, and F-actin content was measured with a flow
cytometer (FACS Calibur, Becton Dickinson, Franklin Lakes, NJ),
as previously described,16 at a mean fluorescent intensity of 5000
cells. The change of F-actin content was expressed as the percent-
age change from the baseline value.
Transit of Whole Blood Through Microchannels
The transit time of whole blood through microchannels was mea-
sured as a surrogate marker of PMN deformability by using a
microchannel array flow analyzer. The microchannels are made of
silicone resembling the size of capillaries (width, 6 m; depth, 4.5
m; length, 10 m; number of channels, 2600). Whole blood
filterability was assessed by measuring the transit time of a purified
100-L sample through the microchannels with a pressure of 10
cm H2O, and the passage was recorded with a videomicroscope.17
Adhesion Molecules Assay
Changes in the surface expression of L-selectin and CD11b of
PMNs were measured by using flow cytometry, as previously
described.16 One hundred microliters of whole blood samples was
incubated for 30 minutes with 2 mg/mL fluorescein isothiocya-
nate–conjugated CD62L antibody (BD Biosciences Pharmingen,
San Diego, Calif) and 1 mg/mL phycoerythrin-conjugated mouse
monoclonal anti-human CD11b antibody (DAKO Corporation,
Carpinteria, Calif) at 4°C. Identical samples were incubated with
fluorescein isothiocyanate–conjugated mouse immunoglobulin
(Ig) G (DAKO) and phycoerythrin-conjugated mouse IgG2a
(DAKO) as a negative control. The erythrocytes were lysed for 60
seconds with Immuno-lyse, and leukocytes were fixed with Im-
muno-fix (commercial kit from Coulter Clone, Coulter Immuno-
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tech). PMNs were identified by the typical forward- and side-
scatter pattern, and the expression of L-selectin and CD11b was
measured as a mean fluorescent intensity of 5000 cells of PMNs.
The changes of L-selectin and CD11b expression were presented
as percentage changes compared with baseline values.
Serum Assays
PMN elastase was measured with an enzyme-linked immunosor-
bent assay kit (MERCK Immunoassay, Whitehouse Station, NJ),
according to the manufacturer’s instructions.
Statistics
Data were analyzed by using a 2-way analysis of variance in a
randomized block design, with time as a repeating factor and donor
as a grouping factor. The sequential rejective Bonferroni test was
used to correct for multiple comparisons.18 All values are ex-
pressed as means  SEM.
Results
Blood Cell Counts
White blood cell counts and hematocrit levels did not
change significantly in either group (data not shown). Plate-
let counts decreased in both the control (23.0%  2.4% of
the baseline value at 120 minutes, P  .001) and rolipram-
treated groups (27.4%  3.9% of the baseline value at 120
minutes, P  .001).
F-actin Content Assay
The F-actin content of PMNs increased to 249.1% 60.1%
of the baseline value at 60 minutes in the control group (P
.032, Figure 1). The F-actin content did not change signif-
icantly in the rolipram-treated group (138.9%  23.7% of
the baseline value at 60 minutes). Rolipram inhibited the
change in the cytoskelton of PMNs induced by simulated
ECC.
Transit of Whole Blood Through Microchannels
The videomicroscope image at 120 minutes showed the
plugging of microchannels with leukocytes and the distur-
bance of red blood cell flow in the control group (Figure 2,
Figure 1. F-actin content of PMNs. The F-actin content of PMNs
increased at 30 and 60 minutes in the control group. The F-actin
content did not increase significantly in the rolipram-treated
group. Rolipram attenuated the change in the cytoskelton of
PMNs induced by simulated ECC. Results are expressed as
means  SEM of 6 experiments. *P  .014, **P  .032 versus
baseline; #P  .042 versus the control group. SC, Standing con-
trol.
Figure 2. The transit of whole blood through microchannels. A,
The videomicroscope image at 120 minutes shows the plugging of
microchannels with leukocytes and the disturbance of red blood
cell flow in the control group. Rolipram reduced this plugging and
kept the flow smooth. B, The transit time of whole blood through
microchannels increased from 30 to 120 minutes in the control
group. The transit time did not increase significantly in the
rolipram-treated group. Results are expressed as means  SEM
of 6 experiments. *P < .001, **P  .001, ***P  .003 versus
baseline; #P  .002 versus the control group. SC, Standing con-
trol.
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A). Rolipram reduced this plugging and kept the flow
smooth. The transit time of whole blood through micro-
channels increased to 179.8%  23.7% of the baseline
value at 120 minutes in the control group (P  .001, Figure
2, B). The transit time did not change significantly in the
rolipram-treated group (128.5%  15.9% of the baseline
value at 120 minutes). Rolipram attenuated the change in
whole blood filterability induced by simulated ECC.
Adhesion Molecules Assay
The expression of L-selectin of PMNs decreased to 17.0%
 3.6% of the baseline value at 120 minutes in the control
group (P  .001; Figure 3, A); rolipram attenuated this
decrease (39.2%  4.7% of the baseline value at 120
minutes, P  .002). The expression of CD11b of PMNs
increased to 574.6%  50.7% of the baseline value at 120
minutes in the control group (P  .001; Figure 3, B);
rolipram inhibited this increase (224.1%  67.1% of the
baseline value at 120 minutes, P  .003). Rolipram inhib-
ited the change in adhesive quality of PMNs induced by
simulated ECC.
Serum Assays
Rolipram reduced the increase of elastase release from
PMNs (control group, 1839  364 g/mL; rolipram-treated
group, 801.3  116.1 g/mL at 120 minutes; P  .042;
Figure 4).
Discussion
Activated PMNs play an important role in the systemic
inflammatory response associated with CPB.1,2 PMNs are
activated by both direct contact with the synthetic surface
and the activated complement.2,19,20 Our results show that
the selective PDE type 4 inhibitor inhibits the activation of
PMNs induced by simulated ECC. This was associated with
the inhibition of the increase in F-actin content, the decrease
in PMN deformability, the decrease in L-selectin expres-
sion, the increase in CD11b expression, and the release of
elastase from PMNs. These phenotypic and functional char-
acteristics of PMNs have all been shown to affect PMN-
mediated organ injuries.5
Simulatad ECC increased the F-actin content of PMNs at
30 and 60 minutes (Figure 1). The change at 120 minutes
was not significant. We speculate that the increase of F-actin
might have diminished by 120 minutes in some experiments
because the increase of F-actin is a transient phenomenon.
Rolipram inhibited this increase in F-actin content of
PMNs. The increase in F-actin content was associated with
the decrease in PMN deformability, which was measured as
the increase in whole blood transit time through microchan-
nels. Rolipram inhibited this decrease in PMN deformabil-
ity induced by simulated ECC. The microchannel array flow
analyzer is a device with uniform silicon channels that
simulates the size of capillaries.17 The passage of PMNs
through these channels was visualized by using videomi-
croscopy (Figure 2, A), and the transit times of whole blood
were compared on the basis of treatment (Figure 2, B). We
have used this whole blood transit time as a surrogate
marker for PMN deformability because PMNs are far less
deformable compared with red blood cells.5 Aggregated
platelets might also affect the transit time. However, there
was no difference in platelet number and aggregation in
response to adenosine diphosphate (5-50 mol/L), as mea-
sured with a platelet aggregometer (model PAC-4S, NBS
Hematracer, Japan), between the control and rolipram-
Figure 3. The expression of L-selectin and CD11b of PMNs. A, The
expression of L-selectin of PMNs decreased in both the control
and rolipram-treated groups. Rolipram attenuated this decrease.
Results are expressed as means  SEM of 6 experiments. *P <
.001, **P < .004 versus baseline; #P  .042, ##P  .002 versus the
control group. B, The expression of CD11b of PMNs increased in
both the control and rolipram-treated groups. Rolipram inhibited
this increase. Results are expressed as means  SEM of 6
experiments. *P < .001, **P  .014, ***P  .034 versus baseline;
#P  .029, ##P  .003 versus the control group. SC, Standing
control.
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treated groups during the experimental period (data not
shown). Therefore, we suspect that PMN deformability
change is the main factor that determines the transit time of
whole blood through microchannels in our experiment. Be-
cause changes in the cytoskeleton with F-actin assembly at
the cell periphery are thought to be responsible for the
deformability change of PMNs,7,8 our results suggest that
rolipram inhibits the deformability change of activated
PMNs by inhibiting F-actin assembly. The deformability
change of PMNs is important in initial sequestration of
PMNs in microvessels.21 Therefore, rolipram is expected to
inhibit initial PMN sequestration.
Simulated ECC decreased the L-selectin expression of
PMNs (Figure 3, A). This is compatible with former studies
with simulated ECC.22 On the other hand, CPB increases23
or does not alter24 the L-selectin expression of PMNs in
clinical settings. We suspect that CPB causes the shedding
of L-selectin from PMNs, which results in the decrease of
L-selectin expression, but the release of L-selectin–rich
PMNs from the bone marrow compensates for the change.25
Simulataed ECC increased the CD11b expression of PMNs
(Figure 3, B), which is compatible with the results of former
studies with simulated ECC22,26 and most clinical stud-
ies.24,27 The selectins slow PMNs by mediating rolling, and
the integrins induce firm adhesion between PMNs and en-
dothelial cells.6 These changes in the adhesive quality of
PMNs are important in prolonged sequestration of PMNs in
microvessels.9 Therefore, rolipram is expected to inhibit
prolonged sequestration of PMNs in microvessels.
Simulated ECC induced the release of elastase from
PMNs (Figure 4), and rolipram significantly inhibited this
release. CPB induces the release of proteases20 and reactive
oxygen species2 from PMNs. The release of elastase and
reactive oxygen species from PMNs sequestered in mi-
crovessels could cause damage to endothelial cells and
induce tissue injury.2 There is a positive correlation between
elastase plasma concentration during CPB and postopera-
tive respiratory dysfunction.28 Our results suggest that roli-
pram could inhibit the endothelial injury caused by PMNs.
In summary, the results of this study show that the
selective PDE type 4 inhibitor rolipram inhibits functional
changes of PMNs in a model of simulated ECC and pro-
motes their sequestration in microvessels. The sequestration
of PMNs in microvessels is a crucial step in PMN-mediated
organ injuries. Rolipram also inhibits the elastase release
from PMNs, which causes endothelial injury. Therefore,
this study suggests that PDE type 4 inhibition could be a
future therapeutic strategy to prevent exaggerated inflam-
matory response and organ injuries related to CPB, although
further experimental work in animal models of CPB is
necessary to determine the effects of PDE 4 inhibition in
vivo.
We thank Dr Stephan F. van Eeden for reviewing the manu-
script and Dr Yuji Kikuchi for direction in the measurement of
PMN transit time through microchannels.
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